CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 400 enrolled / 400 target
Drug / intervention
Sodium Bicarbonatedrug
Likely dose
Sodium Bicarbonate 125mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02476253
NCT02476253Phase 3CompletedHigh Momentum (3.0/mo)Completion was 109mo ago
CompareCT.gov

Sodium Bicarbonate to Treat Severe Acidosis in the Critically Ill : A Multiple Center Randomized Clinical Trial (BICAR-ICU)

University Hospital, Montpellier·interventional·Posted Jun 19, 2015·Updated Jun 15, 2026

In Brief

A Phase 3 clinical trial evaluating Sodium Bicarbonate for Metabolic Acidosis. Completed, enrolled 400 participants across 1 site.

Signals

Enrolling ahead of pace

Detailed Summary

The purpose of the present study is to compare the adjunct treatment of metabolic or mixed severe acidosis in the critically ill using Sodium Bicarbonate as a buffer to increase the plasma pH vs no buffering therapy. The study is a randomized multiple center clinical trial with the outcome as a primary endpoint.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolic Acidosis
CountriesFrance
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 19, 2015
Enrollment StartMay 5, 2015
Primary CompletionMay 29, 2017
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 11.0 years ago

Arms & Interventions

Interventionexperimental

Intravenous 4.2% Sodium Bicarbonate 125ml to 250ml / 30min up to 1000ml/24h to maintain plasma pH equal or greater than 7.30

Drug: Sodium Bicarbonate
Controlno_intervention

No intervention

Interventions

Sodium Bicarbonatedrug

Intravenous 4.2% Sodium Bicarbonate 125ml to 250ml / 30min up to 1000ml/24h to maintain plasma pH equal or greater than 7.30